Acrux Of Australia Eyes Big Win In U.S. Approval For Testosterone Drug
This article was originally published in PharmAsia News
Australia's Acrux could see $1 billion in sales next year for its Axiron (testosterone) supplement delivered as an underarm spray
You may also be interested in...
Inovio forges ahead into Phase I trials with DNA-based vaccine candidate, but can it prove skeptics wrong?
Erectile dysfunction drug sildenafil, plus treatments for skin conditions such as eczema, are among a bounty of Rx-to-OTC switches approved in Switzerland.
Sandoz has appointed a new leader for its Japanese business following the acquisition of Aspen’s local operations, while Stada has brought in a former Sandoz and Pfizer executive to lead its Ciclum Farma unit in Portugal. Meanwhile, Julphar has a new CEO.